A genome-wide investigation of SNPs and CNVs in schizophrenia.

PLoS Genet 2009 Feb 6;5(2):e1000373. Epub 2009 Feb 6.

Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA.

We report a genome-wide assessment of single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) in schizophrenia. We investigated SNPs using 871 patients and 863 controls, following up the top hits in four independent cohorts comprising 1,460 patients and 12,995 controls, all of European origin. We found no genome-wide significant associations, nor could we provide support for any previously reported candidate gene or genome-wide associations. We went on to examine CNVs using a subset of 1,013 cases and 1,084 controls of European ancestry, and a further set of 60 cases and 64 controls of African ancestry. We found that eight cases and zero controls carried deletions greater than 2 Mb, of which two, at 8p22 and 16p13.11-p12.4, are newly reported here. A further evaluation of 1,378 controls identified no deletions greater than 2 Mb, suggesting a high prior probability of disease involvement when such deletions are observed in cases. We also provide further evidence for some smaller, previously reported, schizophrenia-associated CNVs, such as those in NRXN1 and APBA2. We could not provide strong support for the hypothesis that schizophrenia patients have a significantly greater "load" of large (>100 kb), rare CNVs, nor could we find common CNVs that associate with schizophrenia. Finally, we did not provide support for the suggestion that schizophrenia-associated CNVs may preferentially disrupt genes in neurodevelopmental pathways. Collectively, these analyses provide the first integrated study of SNPs and CNVs in schizophrenia and support the emerging view that rare deleterious variants may be more important in schizophrenia predisposition than common polymorphisms. While our analyses do not suggest that implicated CNVs impinge on particular key pathways, we do support the contribution of specific genomic regions in schizophrenia, presumably due to recurrent mutation. On balance, these data suggest that very few schizophrenia patients share identical genomic causation, potentially complicating efforts to personalize treatment regimens.

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pgen.1000373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631150PMC
February 2009
50 Reads

Publication Analysis

Top Keywords

cnvs schizophrenia
12
cnvs
9
genome-wide associations
8
deletions greater
8
provide support
8
schizophrenia patients
8
schizophrenia-associated cnvs
8
controls european
8
cases controls
8
schizophrenia
8
snps cnvs
8
controls
6
provide
5
support
5
evaluation 1378
4
genomic regions
4
reported evaluation
4
schizophrenia finally
4
specific genomic
4
contribution specific
4

References

(Supplied by CrossRef)
Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
WW Fleischhacker et al.
Curr Opin Psychiatry 2006
Migration and schizophrenia.
JP Selten et al.
Curr Opin Psychiatry 2007
Interpreting the association between cannabis use and increased risk for schizophrenia.
M Weiser et al.
Dialogues Clin Neurosci 2005
Schizophrenia after prenatal famine. Further evidence.
E Susser et al.
Arch Gen Psychiatry 1996

Similar Publications